Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy

References

• Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, Lewis WD, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis 2013;8:31
   PubMed Web of Science ®Google Scholar
• Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry 2015;86:1036–43
   PubMed Web of Science ®Google Scholar
• Rowczenio DM, Noor I, Gillmore JD, Lachmann HJ, Whelan C, Hawkins PN, Obici L, et al. Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat 2014;35:E2403–12
   PubMed Web of Science ®Google Scholar
• Coutinho P, Martins da Silva A, Lopes Lima J, Resende Barbosa A. Forty years of experience with type I amyloid neuropathy: review of 483 cases. In: Glenner GG, Pinho e Costa P, Falcao de Freitas A, eds. Amyloid and amyloidosis. Amsterdam: Excerpta Medica; 1980:88–98
   Google Scholar
• Conceição IM, González-Duarte A, Obici L, Harmut HH, Simoneau D, Ong ML, Amass L. “Red-flag” symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst 2015;21:5–9
   Web of Science ®Google Scholar
• Adams D. Recent advances in the treatment of familial amyloid polyneuropathy. Ther Adv Neurol Disord 2013;6:129–39
   PubMed Web of Science ®Google Scholar
• Planté-Bordeneuve V. Update in the diagnosis and management of transthyretin familial amyloid polyneuropathy. J Neurol 2014;261:1227–33
   PubMed Web of Science ®Google Scholar
• Ericzon BG, Wilczek HE, Larsson M, Wijayatunga P, Stangou A, Pena JR, Furtado E, et al. Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation 2015;99:1847–54
   PubMed Web of Science ®Google Scholar
• Hanna M. Novel drugs targeting transthyretin amyloidosis. Curr Heart Fail Rep 2014;11:50–7
   PubMedGoogle Scholar
• Sekijima Y, Tojo K, Morita H, Koyama J, Ikeda S. Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis. Amyloid 2015;22:79–83
   PubMed Web of Science ®Google Scholar
• Scott LJ. Tafamidis: a review of its use in familial amyloid polyneuropathy. Drugs 2014;74:1371–8
   PubMed Web of Science ®Google Scholar
• Waddington Cruz M, Benson M. A review of tafamidis for the treatment of transthyretin-related amyloidosis. Neurol Ther 2015;4:61–79
   PubMed Web of Science ®Google Scholar
• Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Planté-Bordeneuve V, Lozeron P, Suhr OB, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012;79:785–92
   PubMed Web of Science ®Google Scholar
• Coelho T, Maia LF, da Silva AM, Cruz MW, Planté-Bordeneuve V, Suhr OB, Conceicao I, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 2013;260:2802–14
   PubMed Web of Science ®Google Scholar
• Coelho T, Merkies I, Vinik A, Vinik EJ, Chan J, Packman J, Grogan DR. Relationship between objective measures of neuropathy and quality of life in stages of severity of transthyretin familial amyloid polyneuropathy. Abstract P-098 of the XII International Symposium on Amyloidosis, April 18–21, 2010, Rome, Italy. Amyloid 2010;17 Suppl 1:138
   Google Scholar
• Suhr OB, Conceição IM, Karayal ON, Mandel FS, Huertas PE, Ericzon BG. Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurol Ther 2014;3:101–12
   PubMedGoogle Scholar
• Dyck PJ, Davies JL, Litchy WJ, O’Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 1997;49:229–39
   PubMed Web of Science ®Google Scholar
• Suhr O, Danielsson A, Holmgren G, Steen L. Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. J Intern Med 1994;235:479–85
   PubMed Web of Science ®Google Scholar
• Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, Heneghan MA, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 2013;310:2658–67
   PubMed Web of Science ®Google Scholar